These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22614325)

  • 21. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
    Kelleher FC; McDermott R
    Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
    Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
    Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.
    Thunnissen E; Bubendorf L; Dietel M; Elmberger G; Kerr K; Lopez-Rios F; Moch H; Olszewski W; Pauwels P; Penault-Llorca F; Rossi G
    Virchows Arch; 2012 Sep; 461(3):245-57. PubMed ID: 22825000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.
    Mesaros EF; Ott GR; Dorsey BD
    Expert Opin Ther Pat; 2014 Apr; 24(4):417-42. PubMed ID: 24476492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anaplastic lymphoma kinase as a therapeutic target.
    Kruczynski A; Delsol G; Laurent C; Brousset P; Lamant L
    Expert Opin Ther Targets; 2012 Nov; 16(11):1127-38. PubMed ID: 22998583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
    Huang Q; Johnson TW; Bailey S; Brooun A; Bunker KD; Burke BJ; Collins MR; Cook AS; Cui JJ; Dack KN; Deal JG; Deng YL; Dinh D; Engstrom LD; He M; Hoffman J; Hoffman RL; Johnson PS; Kania RS; Lam H; Lam JL; Le PT; Li Q; Lingardo L; Liu W; Lu MW; McTigue M; Palmer CL; Richardson PF; Sach NW; Shen H; Smeal T; Smith GL; Stewart AE; Timofeevski S; Tsaparikos K; Wang H; Zhu H; Zhu J; Zou HY; Edwards MP
    J Med Chem; 2014 Feb; 57(4):1170-87. PubMed ID: 24432909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
    Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B
    J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
    Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
    World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component.
    Yoshida A; Tsuta K; Watanabe S; Sekine I; Fukayama M; Tsuda H; Furuta K; Shibata T
    Lung Cancer; 2011 Jun; 72(3):309-15. PubMed ID: 21036415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.
    Sugawara E; Togashi Y; Kuroda N; Sakata S; Hatano S; Asaka R; Yuasa T; Yonese J; Kitagawa M; Mano H; Ishikawa Y; Takeuchi K
    Cancer; 2012 Sep; 118(18):4427-36. PubMed ID: 22252991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
    Sakamoto H; Tsukaguchi T; Hiroshima S; Kodama T; Kobayashi T; Fukami TA; Oikawa N; Tsukuda T; Ishii N; Aoki Y
    Cancer Cell; 2011 May; 19(5):679-90. PubMed ID: 21575866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
    Lee JA; Bubendorf L; Stahel R; Peters S
    Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
    Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
    Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New targets in advanced NSCLC: EML4-ALK.
    Crystal AS; Shaw AT
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):207-14. PubMed ID: 21475126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?
    Crystal AS; Shaw AT
    Clin Cancer Res; 2012 Sep; 18(17):4479-81. PubMed ID: 22912388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virtual screening and further development of novel ALK inhibitors.
    Okamoto M; Kojima H; Saito N; Okabe T; Masuda Y; Furuya T; Nagano T
    Bioorg Med Chem; 2011 May; 19(10):3086-95. PubMed ID: 21515061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK.
    Sun HY; Ji FQ
    Biochem Biophys Res Commun; 2012 Jun; 423(2):319-24. PubMed ID: 22659414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
    Okubo J; Takita J; Chen Y; Oki K; Nishimura R; Kato M; Sanada M; Hiwatari M; Hayashi Y; Igarashi T; Ogawa S
    Oncogene; 2012 Nov; 31(44):4667-76. PubMed ID: 22249260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of the ALK receptor in cancer biology.
    Hallberg B; Palmer RH
    Ann Oncol; 2016 Sep; 27 Suppl 3():iii4-iii15. PubMed ID: 27573755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
    Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
    J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.